Biogen Inc PS Ratio & PS Ratio Charts - BIIB

Current and historical daily PS Ratio for Biogen Inc ( ) from 1991 to Jul 21 2026. The price to sales ratio is calculated by taking the current stock price and dividing it by the trailing twelve-month sales per share. The data is updated every 20 minutes during market hours. The PS ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS ratio is a great valuation tool for evaluating cyclical businesses where the PE ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean. Biogen stock (BIIB) PS ratio as of Jul 21 2026 is 2.98. More Details

Biogen Inc (BIIB) PS Ratio Chart

Biogen Inc (BIIB) PS Ratio Historical Data

View and export this data going back to 1991. Start your Free Trial

Total 1207

Biogen PS Ratio Historical Data
Date	PS Ratio Data	Date	PS Ratio Data
2026-07-21	3.0	3.02	2.95	3	2026-05-14	3.0	3.04	2.81	2.84
2026-07-20	3.0	3.05	2.96	2.97	2026-05-13	3.0	3.06	2.95	3.04
2026-07-17	3.1	3.2	3.02	3.06	2026-05-12	3.0	3	2.92	2.96
2026-07-16	2.9	3.11	2.89	3.1	2026-05-11	2.9	2.97	2.89	2.94
2026-07-15	2.8	2.95	2.76	2.93	2026-05-08	2.8	2.9	2.81	2.87
2026-07-14	3.0	3	2.81	2.85	2026-05-07	2.8	2.85	2.8	2.84
2026-07-13	3.0	3.13	2.94	3.1	2026-05-06	2.8	2.84	2.8	2.83
2026-07-10	2.9	2.97	2.89	2.96	2026-05-05	2.8	2.82	2.76	2.81
2026-07-09	3.0	2.98	2.91	2.95	2026-05-04	2.8	2.78	2.75	2.78
2026-07-08	3.0	3.07	2.95	2.97	2026-05-01	2.8	2.83	2.76	2.78
2026-07-07	3.1	3.15	3.05	3.05	2026-04-30	2.9	2.91	2.78	2.81
2026-07-06	3.2	3.21	3.09	3.09	2026-04-29	2.7	2.91	2.67	2.89
2026-07-02	3.2	3.25	3.13	3.21	2026-04-28	2.7	2.74	2.7	2.72
2026-07-01	3.2	3.2	3.11	3.11	2026-04-27	2.7	2.76	2.66	2.68
2026-06-30	3.2	3.24	3.16	3.21	2026-04-24	2.8	2.77	2.72	2.74
2026-06-29	3.2	3.26	3.18	3.22	2026-04-23	2.8	2.83	2.78	2.79
2026-06-26	3.0	3.24	3	3.21	2026-04-22	2.8	2.86	2.8	2.82
2026-06-25	3.0	3.07	2.97	3	2026-04-21	2.7	2.79	2.7	2.76
2026-06-24	3.0	3	2.95	2.96	2026-04-20	2.7	2.74	2.65	2.72
2026-06-23	3.0	2.99	2.92	2.93	2026-04-17	2.6	2.65	2.61	2.63
2026-06-22	3.0	2.98	2.89	2.96	2026-04-16	2.6	2.67	2.6	2.61
2026-06-18	3.0	2.98	2.87	2.92	2026-04-15	2.7	2.69	2.64	2.68
2026-06-17	2.9	3	2.88	2.95	2026-04-14	2.6	2.7	2.63	2.66
2026-06-16	3.0	2.97	2.88	2.9	2026-04-13	2.6	2.62	2.54	2.62
2026-06-15	2.9	2.96	2.91	2.95	2026-04-10	2.6	2.64	2.56	2.57
2026-06-12	3.0	3.02	2.96	2.97	2026-04-09	2.6	2.67	2.6	2.63
2026-06-11	2.9	2.99	2.88	2.97	2026-04-08	2.6	2.68	2.62	2.67
2026-06-10	3.0	3	2.88	2.88	2026-04-07	2.6	2.61	2.53	2.61
2026-06-09	2.9	2.96	2.87	2.96	2026-04-06	2.6	2.63	2.5	2.56
2026-06-08	2.9	2.95	2.85	2.86	2026-04-02	2.7	2.71	2.62	2.63
2026-06-05	2.9	2.98	2.9	2.9	2026-04-01	2.7	2.77	2.7	2.73
2026-06-04	2.9	2.97	2.91	2.92	2026-03-31	2.7	2.74	2.54	2.72
2026-06-03	2.8	2.92	2.78	2.91	2026-03-30	2.8	2.82	2.75	2.78
2026-06-02	2.8	2.83	2.74	2.8	2026-03-27	2.8	2.84	2.72	2.73
2026-06-01	2.9	2.9	2.85	2.85	2026-03-26	2.8	2.86	2.8	2.84
2026-05-29	2.9	2.95	2.9	2.91	2026-03-25	2.8	2.82	2.75	2.81
2026-05-28	2.9	2.94	2.89	2.92	2026-03-24	2.7	2.75	2.68	2.74
2026-05-27	2.9	2.97	2.88	2.92	2026-03-23	2.7	2.75	2.72	2.73
2026-05-26	2.9	2.9	2.85	2.87	2026-03-20	2.7	2.73	2.68	2.7
2026-05-22	2.8	2.89	2.82	2.88	2026-03-19	2.7	2.76	2.7	2.73
2026-05-21	2.8	2.82	2.76	2.81	2026-03-18	2.7	2.74	2.68	2.71
2026-05-20	2.8	2.87	2.77	2.79	2026-03-17	2.8	2.77	2.72	2.76
2026-05-19	2.9	2.87	2.8	2.83	2026-03-16	2.7	2.75	2.7	2.73
2026-05-18	2.8	2.87	2.81	2.85	2026-03-13	2.8	2.8	2.7	2.7
2026-05-15	2.9	2.89	2.83	2.86	2026-03-12	2.8	2.81	2.75	2.75

Biogen Inc (BIIB) PS Ratio Comparison

Company	Market Cap(Mil)	PS Ratio

Business Description

Biogen Inc

NAICS : 325412 SIC : 2834
ISIN : US09062X1037

https://www.biogen.com

225 Binney Street, Cambridge, MA, USA, 02142

Total Employee Number:

7,500

Compare

OGNAMRNSCLXMIRANSRXMDCXBMYPFEGILDLLYJNJABBVXSWX:ROPMRKXSWX:NOVNLSE:AZNOCSE:NOVO BAMGNLSE:GSKXPAR:SAN

Traded in other countries / regions

BIIB.USABIIB.Argentina0R1B.UKBIIB.MexicoBIIB34.BrazilIDP.Germany1BIIB.ItalyBIIB.AustriaBIIB_KZ.KazakhstanBIIB.SwitzerlandBIIB.Chile

Index Membership

S&P 500 Russell 1000 Russell 3000 MSCI World Index NASDAQ 100

IPO Date

1991-09-17

Description

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.